Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease 3 (Dan-NICAD 3)
In a cohort of symptomatic patients referred to coronary computed tomography angiography (CCTA), the investigators aim is:
- To investigate and compare the diagnostic precision of Rubidium Positron Emission Tomography (Rb PET) and 15O-water PET (15O-water PET) in patients where CCTA does not exclude obstructive coronary artery disease (CAD) using invasive coronary angiography with fractional flow reserve (ICA-FFR) as reference standard.
- To study the diagnostic accuracy and prognostic value of computed tomography fractional flow reserve (CT-FFR) in patients where CCTA does not exclude obstructive CAD with ICA-FFR as reference standard.
- To validated a pre-test probability model including genetic and circulating biomarkers.
- To identify and characterize genetic risk variants and circulating biomarkers importance in developing CAD.
- To evaluate the bone mineral density in the hip and spine and correlate this to the degree of vascular calcification.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
CCTA has become the preferred diagnostic modality for symptomatic patients with low to intermediate risk of CAD. Of the patients examined, CCTA exclude cardiovascular disease in 70-80% with an excellent negative predictive value of more than 95%. Having a low positive predictive value, however, CCTA often overestimates the severity of CAD, especially in patients with moderate to severe coronary calcification. Following CCTA, patients are hence unnecessarily tested using golden standard ICA-FFR. These ICAs often show no obstructive coronary stenosis and are therefore not followed by revascularization. The issues outlined raises the question of whether it is possible (1) to make a more precise risk stratification and consequently better selection of patients prior to CCTA and (2) to reduce the number of patients referred for unnecessary ICAs following CCTA.
In patients with suspicion of coronary stenosis detected by CCTA, current guidelines recommend verification of myocardial ischemia. Dan-NICAD 3 investigate the diagnostic accuracy of advanced non-invasive myocardial perfusion imaging tests; Rb PET and 15O-water PET. These examinations have shown a high diagnostic accuracy in symptomatic patients with high risk of ischemic heart disease. However, the diagnostic accuracy is not investigated in patients as follow-up after CCTA. In addition, microcirculation may impact the correlation between PET and ICA-FFR which this study will investigate further.
An alternative way to increase the diagnostic accuracy of CCTA and thus avoid unnecessary downstream testing using ICA is to utilize the ability to extract physiological information from the anatomical CCTA images. CT-FFR has in previous studies shown promising results. In addition, calculated estimation of microcirculatiory function is under development and this study will validated these algorithms. Furthermore, the prognostic value of CT-FFR is unknown and will be tested in the pooled cohort of Dan-NICAD 1, 2 and 3.
Obtained during ICA, quantitative flow ratio (QFR) is a novel wire-free approach for fast computation of FFR with potential to increase the global use of physiological lesion assessment. QFR is superior to traditional assessment of intermediate coronary lesions based on quantitative coronary analysis of ICA. However, disagreement between ICA-FFR and QFR has been identified in up to 20% of all measurements. QFR will be validated compared to PET and ICA-FFR.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Luoghi di studio
-
-
-
Herning, Danimarca, 7400
- Reclutamento
- Gødstrup Hospital
-
Contatto:
- Simon Winther, MD, PhD
- Email: simwin@rm.dk
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
- Inclusion Criteria:
Patients with an indication for CCTA. Qualified patients who have signed a written informed consent form.
- Exclusion Criteria:
Demography and co-existing cardiac morbidity specific: Age below 30 years, patients having a donor heart, a mechanic heart, or mechanical heart pump, suspicion acute coronary syndrome or previous revascularization.
CCTA: Pregnant women, including women who are potentially pregnant or lactating, reduced kidney function, with an estimated glomerular filtration rate (eGFR) < 40 mL/min or allergy to X-ray contrast medium.
PET: contra-indication for adenosine (severe asthma, advanced atrioventricular block, or critical aorta stenosis).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Cohort
Participants consenting to the study will undergo: a1) An interview a2) Blood samples withdrawals a3) ECG a4) Non-enhanced CT a5) CCTA a6) Follow-up for > 10 years Patients with suspicion of coronary stenosis detected by CCTA will after undergo: b1) Rb PET b2) 15O-water PET b3) Invasive coronary angiography with 3 vessel measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microvascular resistance (IMR) |
Head to head comparison with invasive FFR as reference.
Adjustment for abnormal microcirculation
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Diagnostic accuracy of Rb PET and 15-O PET
Lasso di tempo: ICA: 4 weeks after inclusion
|
Head-to-head comparison using ICA-FFR as reference standard stratified for CFR
|
ICA: 4 weeks after inclusion
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Diagnostic accuracy of QFR vs. ICA-FFR
Lasso di tempo: ICA: 4 weeks after inclusion
|
Head-to-head comparison using ICA-FFR as reference standard
|
ICA: 4 weeks after inclusion
|
|
Pre-test probability model of CAD
Lasso di tempo: ICA: 4 weeks after inclusion
|
Advanced pre-test probability model of CAD included clinical information, genetic and circulating biomarkers
|
ICA: 4 weeks after inclusion
|
|
Diagnostic accuracy of QFR
Lasso di tempo: ICA: 4 weeks after inclusion
|
Head-to-head comparison using ICA-FFR as reference standard
|
ICA: 4 weeks after inclusion
|
|
Diagnostic accuracy of CT-FFR
Lasso di tempo: ICA: 4 weeks after inclusion
|
Head-to-head comparison with PET using ICA-FFR as reference standard
|
ICA: 4 weeks after inclusion
|
|
Effect of reduced myocardial perfusion defect on symptoms of angina pectoris
Lasso di tempo: Re-PET: 12 months after inclusion
|
12 months re-PET investigation will by used for estimation of reduction of myocardial perfusion defect size which will be correlated with symptoms of angina pectoris 3 and 12 mdr.
after ICA
|
Re-PET: 12 months after inclusion
|
|
Prognostic value of clinical, biomarker, genetic information
Lasso di tempo: Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
|
Prognotic models will be developed based on machine learning algorithms
|
Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
|
|
Prognostic value of clinical markers, CCTA, Rb PET, 15O-water PET, CT-FFR and QFR
Lasso di tempo: Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
|
Prognotic models will be developed based on machine learning algorithms
|
Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
|
|
Predictive models of obstructive CAD
Lasso di tempo: ICA: 4 weeks after inclusion
|
Development of pre-test probability models of obstructive CAD at ICA
|
ICA: 4 weeks after inclusion
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Simon Winther, MD, PhD, Hospital Unit West, Herning, Denmark
Pubblicazioni e link utili
Pubblicazioni generali
- Nissen L, Winther S, Isaksen C, Ejlersen JA, Brix L, Urbonaviciene G, Frost L, Madsen LH, Knudsen LL, Schmidt SE, Holm NR, Maeng M, Nyegaard M, Botker HE, Bottcher M. Danish study of Non-Invasive testing in Coronary Artery Disease (Dan-NICAD): study protocol for a randomised controlled trial. Trials. 2016 May 26;17(1):262. doi: 10.1186/s13063-016-1388-z.
- Rasmussen LD, Winther S, Westra J, Isaksen C, Ejlersen JA, Brix L, Kirk J, Urbonaviciene G, Sondergaard HM, Hammid O, Schmidt SE, Knudsen LL, Madsen LH, Frost L, Petersen SE, Gormsen LC, Christiansen EH, Eftekhari A, Holm NR, Nyegaard M, Chiribiri A, Botker HE, Bottcher M. Danish study of Non-Invasive testing in Coronary Artery Disease 2 (Dan-NICAD 2): Study design for a controlled study of diagnostic accuracy. Am Heart J. 2019 Sep;215:114-128. doi: 10.1016/j.ahj.2019.03.016. Epub 2019 May 1.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Dan-NICAD 3
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .